L-Carnosine Modulates Respiratory Burst and Reactive Oxygen Species Production in Neutrophil Biochemistry and Function: May Oral Dosage Form of Non-Hydrolized Dipeptide L-Carnosine Complement Anti-Infective Anti-Influenza Flu Treatment, Prevention and Self-Care as an Alternative to the Conventional Vaccination?

被引:10
作者
Babizhayev, Mark A. [1 ,2 ]
Deyev, Anatoliy I. [1 ]
Yegorov, Yegor E. [3 ]
机构
[1] Innovat Vis Prod Inc, New Castle, DE 19810 USA
[2] Moscow Helmholtz Res Inst Eye Dis, Moscow 103064, Russia
[3] Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia
来源
CURRENT CLINICAL PHARMACOLOGY | 2014年 / 9卷 / 02期
关键词
Anserine; antigenic specificity in hemagglutinin ligand; cytokines and chemokines; global influenza surveillance; influenza A flu virus infection; influenza vaccines; isopeptide (gamma-glutamyl-carnosine); non-hydrolized oral forms of carnosine; pandemic influenza therapeutic prevention; polymorphonuclear neutrophils; reactive oxygen species;
D O I
10.2174/1574884709999140311125601
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Influenza A is a viral disease of global dimension, presenting with high morbidity and mortality in annual epidemics, and in pandemics which are of infrequent occurrence but which have very high attack rates. Influenza vaccines of the future must be directed toward use of conserved group-specific viral antigens, such as are present in transitional proteins which are exposed during the fusion of virus to the host cell. Influenza probes revealed a continuing battle for survival between host and parasite in which the host population updates the specificity of its pool of humoral immunity by contact with and response to infection with the most recent viruses which possess altered antigenic specificity in their hemagglutinin (HA) ligand. It is well known that the HA protein is found on the surface of the influenza virus particle and is responsible for binding to receptors on host cells and initiating infection. Polymorphonuclear neutrophils (PMN) have been reported to be involved in the initial host response to influenza A virus (IAV). Early after IAV infection, neutrophils infiltrate the airway probably due to release of chemokines that attract PMN. Clearly, severe IAV infection is characterized by increased neutrophil influx into the lung or upper respiratory tract. Carnosine (beta-alanyl-L-histidine) and anserine (N-beta-alanyl-1-methyl-L-histidine) are found in skeletal muscle of most vertebrates, including those used for food; for example, 100 g of chicken breast contains 400 mg (17.6 mmol/L) of carnosine and 1020 mg (33.6 mmol/l) of anserine. Carnosine-stimulated respiratory burst in neutrophils is a universal biological mechanism of influenza virus destruction. Our own studies revealed previously unappreciated functional effects of carnosine and related histidine containing compounds as a natural biological prevention and barrier against Influenza virus infection, expand public understanding of the antiviral properties of imidazole-containing dipeptide based compounds, and suggest important interactions between neutrophills and carnosine related compounds in the host response to viruses and bacteria. Carnosine and anserine were also found to reduce apoptosis of human neutrophils. In this way these histidine-containing compounds can modulate the Influenza virus release from neutrophills and reduce virus dissemination through the body of the organism. This review points the ability of therapeutic control of Influenza viral infections associated with modulation by oral nonhydrolized forms of carnosine and related histidine-containg compounds of PMN apoptosis which may be involved at least in part in the pathophysiology of the disease in animals and humans. The data presented in this article, overall, may have implications for global influenza surveillance and planning for pandemic influenza therapeutic prevention with oral forms of non-hydrolized natural L-carnosine as a suitable alternative to the conventional vaccination for various flu ailments.
引用
收藏
页码:93 / 115
页数:23
相关论文
共 121 条
[1]   Carnosine and related dipeptides as quenchers of reactive carbonyl species: From structural studies to therapeutic perspectives [J].
Aldini, G ;
Facino, RM ;
Beretta, G ;
Carini, M .
BIOFACTORS, 2005, 24 (1-4) :77-87
[2]   Profiling histidine-containing dipeptides in rat tissues by liquid chromatography/electrospray ionization tandem mass spectrometry [J].
Aldini, G ;
Orioli, M ;
Carini, M ;
Facino, RM .
JOURNAL OF MASS SPECTROMETRY, 2004, 39 (12) :1417-1428
[3]   Recent zoonoses caused by influenza A viruses [J].
Alexander, DJ ;
Brown, IH .
REVUE SCIENTIFIQUE ET TECHNIQUE-OFFICE INTERNATIONAL DES EPIZOOTIES, 2000, 19 (01) :197-225
[4]  
[Anonymous], 2008, TAM PROD INF
[5]   Biological activities of the natural imidazole-containing peptidomimetics n-acetylcamosine, carcinine and L-carnosine in ophthalmic and skin care products [J].
Babizhayev, MA .
LIFE SCIENCES, 2006, 78 (20) :2343-2357
[6]   Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops [J].
Babizhayev, MA .
REJUVENATION RESEARCH, 2004, 7 (03) :186-198
[7]   N-acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts [J].
Babizhayev, MA ;
Deyev, AI ;
Yermakova, VN ;
Semiletov, YA ;
Davydova, NG ;
Kurysheva, NI ;
Zhukotskii, AV ;
Goldman, IM .
PEPTIDES, 2001, 22 (06) :979-994
[8]   L-CARNOSINE (BETA-ALANYL-L-HISTIDINE) AND CARCININE (BETA-ALANYLHISTAMINE) ACT AS NATURAL ANTIOXIDANTS WITH HYDROXYL-RADICAL-SCAVENGING AND LIPID-PEROXIDASE ACTIVITIES [J].
BABIZHAYEV, MA ;
SEGUIN, MC ;
GUEYNE, J ;
EVSTIGNEEVA, RP ;
AGEYEVA, EA ;
ZHELTUKHINA, GA .
BIOCHEMICAL JOURNAL, 1994, 304 :509-516
[9]   Imidazole-containing peptidomimetic NACA as a potent drug for the medicinal treatment of age-related cataract in humans [J].
Babizhayev, MA ;
Yermakova, VN ;
Deyev, AI ;
Seguin, MC .
JOURNAL OF ANTI-AGING MEDICINE, 2000, 3 (01) :43-62
[10]  
Babizhayev MA, 2003, Combined use of carnosinase inhibitor with L-carnosines and composition, Patent No. [2004064866, WO 2004/064866]